Should I Buy DOC? DOC 2026 Analysis

Should You Buy Healthpeak Properties Inc (DOC) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Buy

Latest Price

17.140

1 Day change

-0.06%

52 Week Range

21.280

Analysis Updated At

2026/01/28

BUY now for a beginner, long-term investor primarily seeking income. DOC is pulling back toward a key support zone (~16.99–17.15) while offering an elevated dividend yield (news cites ~6.8%) and a credible value-unlocking catalyst (planned senior housing IPO). With recent Street targets around $19–$20 (roughly ~10–15% upside from ~$17.2) and options flow leaning call-heavy, the risk/reward is favorable for initiating a long-term position immediately with $50k–$100k available.

Technical Analysis

Price/Trend: DOC is in a near-term pullback (regular session -3.16%) with a small post-market rebound (+1.05% to ~17.33). It’s trading just below the pivot (17.541) and close to first support S1 (16.989), which often becomes a practical “buy zone” if it holds. Momentum: RSI(6) ~35.7 is weak but not deeply oversold—consistent with a selloff that may be closer to stabilizing than accelerating. MACD histogram is positive (0.0466) but contracting, suggesting upside momentum has cooled and the stock is trying to base rather than trend strongly. Levels: Support: 16.99 (S1), then 16.65 (S2). Resistance: 17.54 (pivot), then 18.09 (R1) and 18.43 (R2). A reclaim of ~17.54 improves the near-term setup; holding ~16.99 reduces downside risk. Pattern-based stats: Similar-pattern analysis suggests modest near-term drift (next day -0.15%), but a more favorable skew over 1 week (+1.09%) and 1 month (+8.56%), aligning with a “buy on weakness for longer-term income + recovery” profile. **Intellectia Proprietary Trading Signals** - [AI Stock Picker](module://ai_stock_pick): No signal on given stock today. - [SwingMax](module://swingmax): No signal on given stock recently.

Options Data

Neutral

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Sentiment read: Open interest put-call ratio ~0.98 is essentially neutral positioning (balanced hedging), while the put-call ratio on *volume* ~0.45 indicates calls dominated today’s trading (more bullish/“risk-on” tone). Volatility/positioning: 30D implied vol ~32.13 vs historical vol ~27.16 implies options are pricing elevated near-term uncertainty. IV percentile ~93 is very high versus the past year, which often happens around event/catalyst periods; it also means options are expensive (good for sellers, less attractive for buyers). Overall, the options tape looks mildly bullish (call-heavy volume) but with elevated uncertainty pricing.

Technical Summary

Sell

Buy

Positive Catalysts

1) Dividend/income narrative strengthening: Healthpeak shifted to monthly dividends and is cited with an attractive ~6.8% yield, supporting long-term income-focused demand.
2) Event-driven upside: Planned IPO to unlock value in its senior housing portfolio could surface asset value and improve the market’s sum-of-the-parts perception.
3) Technical location: Price is near first support (~16.99) after a sharp down day, which can attract dip-buying if support holds.
4) Options flow: Call-heavy daily options volume (put-call volume ratio ~0.45) suggests traders are leaning bullish short-term.

Neutral/Negative Catalysts

1) Recent session weakness: -3.16% regular-session move signals near-term negative momentum and potential overhead supply until the stock regains the ~17.54 pivot.
2) Elevated implied volatility: Very high IV percentile (~93) indicates the market is pricing uncertainty; that can coincide with choppy price action.
3) Latest reported profitability metrics are weak: Net income and EPS were negative in the latest quarter snapshot, which can weigh on sentiment even if REIT accounting can be noisy.
4) No supportive positioning signal from insiders/hedge funds: Reported as neutral, so there’s no strong “smart money” accumulation signal in the provided data.

Financial Performance

Latest quarter provided: 2025/Q3. - Revenue: $705.873M (+0.78% YoY) — modest top-line growth. - Net Income: -$117.256M (down -236.86% YoY) — moved deeper into loss. - EPS: -$0.17 (down -241.67% YoY) — materially weaker YoY. - Gross Margin: 58.65% (down -2.12% YoY) — slight margin compression. Takeaway: Revenue is stable-to-slightly growing, but profitability metrics deteriorated notably in this snapshot. For a long-term beginner investor, the bullish case leans more on income + portfolio/catalyst execution (monthly dividend, senior housing value unlock) than on near-term earnings power from this single-quarter view. Upcoming: Earnings listed for 2026-02-02 (after hours).

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent trend (provided): - 2025-11-12: Baird maintained Outperform; price target trimmed to $20 from $21 (slight caution after Q3). - 2025-11-25: Wells Fargo maintained Equal Weight; price target raised to $19 from $18 (mildly improving view). Net read: Targets cluster around $19–$20 with ratings split between Neutral (Equal Weight) and Bullish (Outperform). The pros’ bull case is consistent operating conditions in the REIT space and room for upside to targets from ~$17. The cons implied by the mixed ratings/target trim are that upside may be steady rather than explosive and depends on execution plus sentiment toward rates/REITs. Influential/political trading: No recent congress trading data available; no politician activity provided. Hedge funds and insiders are reported neutral with no significant recent trends.

12 Analyst Rating

Wall Street analysts forecast DOC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DOC is 19.23 USD with a low forecast of 16.71 USD and a high forecast of 21 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Buy

6 Hold

0 Sell

Moderate Buy

Current: 17.150

Low

16.71

Averages

19.23

High

Current: 17.150

Low

16.71

Averages

19.23

High

Wells Fargo

John Kilichowski

Equal Weight

maintain

$18 -> $19

AI Analysis

2025-11-25

Reason

Wells Fargo

John Kilichowski

Price Target

$18 -> $19

AI Analysis

2025-11-25

maintain

Equal Weight

Reason

Wells Fargo analyst John Kilichowski raised the firm's price target on Healthpeak Properties to $19 from $18 and keeps an Equal Weight rating on the shares. The firm says that despite a few high-profile exceptions, most REITs delivered Q3 2025 earnings and outlooks reflecting healthy operating conditions despite macro and labor market concerns.

Baird

Wesley Golladay

Outperform -> Outperform

downgrade

$21 -> $20

2025-11-12

Reason

Baird

Wesley Golladay

Price Target

$21 -> $20

2025-11-12

downgrade

Outperform -> Outperform

Reason

Baird analyst Wesley Golladay lowered the firm's price target on Healthpeak Properties to $20 from $21 and keeps an Outperform rating on the shares. The firm updated its model following Q3 results.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for DOC

Unlock Now

DOC Should I Buy

DOC Should I Buy

Should You Buy Healthpeak Properties Inc (DOC) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch